Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. (GBT) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · GBT · as of Jun 9, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
4
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Global Blood Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
GBT insider buying and selling by quarter
GBT insider selling · GBT insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Recent insider transactions
GBT executive sell shares · GBT board member insider trading · GBT insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Sep 28, 2022 | JOHNSON DAVID LEE Chief Commercial Officer | Gift | 22,000 | — | Form 4 |
| Oct 1, 2022 | Habibizad Nazila See Remarks | Option | 182 | — | Form 4 |
| Oct 1, 2022 | Habibizad Nazila See Remarks | Option | 1,375 | — | Form 4 |
| Sep 29, 2022 | Habibizad Nazila See Remarks | Gift | 3,500 | — | Form 4 |
| Sep 27, 2022 | Farrow Jeffrey S CFO | Option | 23,653 | $388K | Form 4 |
| Sep 27, 2022 | Habibizad Nazila See Remarks | Option | 83 | $4K | Form 4 |
| Sep 27, 2022 | Habibizad Nazila See Remarks | Option | 1,027 | $50K | Form 4 |
| Sep 27, 2022 | Habibizad Nazila See Remarks | Option | 2,043 | $122K | Form 4 |
| Sep 27, 2022 | Habibizad Nazila See Remarks | Option | 3,005 | $89K | Form 4 |
| Sep 27, 2022 | Habibizad Nazila See Remarks | Option | 23,597 | $306K | Form 4 |
| Sep 9, 2022 | LOVE TED W President and CEO · Director | Gift | 221,200 | — | Form 4 |
| Sep 27, 2022 | LOVE TED W President and CEO · Director | Option | 18,291 | $300K | Form 4 |
| Sep 13, 2022 | LOVE TED W President and CEO · Director | Gift | 35,300 | — | Form 4 |
| Sep 13, 2022 | LOVE TED W President and CEO · Director | Gift | 17,650 | — | Form 4 |
| Sep 27, 2022 | Choi Jung See Remarks | Option | 2,674 | $9K | Form 4 |
| Sep 27, 2022 | Choi Jung See Remarks | Option | 2,674 | $9K | Form 4 |
| Sep 27, 2022 | Choi Jung See Remarks | Option | 74,964 | $255K | Form 4 |
| Sep 29, 2022 | Choi Jung See Remarks | Gift | 73,855 | — | Form 4 |
| Sep 27, 2022 | Choi Jung See Remarks | Option | 2,275 | $150K | Form 4 |
| Sep 27, 2022 | Choi Jung See Remarks | Option | 16,902 | $277K | Form 4 |
| Sep 1, 2022 | Habibizad Nazila See Remarks | Option | 2,208 | — | Form 4 |
| Sep 1, 2022 | Habibizad Nazila See Remarks | Other | 1,342 | $91K | Form 4 |
| Sep 1, 2022 | Habibizad Nazila See Remarks | Award | 414 | $11K | Form 4 |
| Sep 1, 2022 | JOHNSON DAVID LEE Chief Commercial Officer | Option | 2,208 | — | Form 4 |
| Sep 1, 2022 | JOHNSON DAVID LEE Chief Commercial Officer | Other | 2,103 | $143K | Form 4 |
JOHNSON DAVID LEE
Chief Commercial Officer
Date
Sep 28
Shares
22,000
Price
—
Value
—
LOVE TED W
President and CEO · Director
Date
Sep 27
Shares
18,291
Price
$16.40
Value
$300K
JOHNSON DAVID LEE
Chief Commercial Officer
Date
Sep 1
Shares
2,208
Price
—
Value
—
JOHNSON DAVID LEE
Chief Commercial Officer
Date
Sep 1
Shares
2,103
Price
$68.15
Value
$143K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About GBT insider trading
GBT insider trades
Global Blood Therapeutics, Inc. (GBT) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including GBT. Over the past 12 months, 0 insiders have filed transactions with the SEC. GBT insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Global Blood Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
GBT insider trading · 5 questionsThe insiders of Global Blood Therapeutics, Inc. (GBT) include executives and directors such as GBT, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026